open access

Vol 14, No 6 (2018)
Review paper
Published online: 2019-03-15
Get Citation

Ewing sarcoma

Tomasz Świtaj, Paulina Jagodzińska-Mucha
DOI: 10.5603/OCP.2018.0052
·
Oncol Clin Pract 2018;14(6):392-398.

open access

Vol 14, No 6 (2018)
REVIEW ARTICLES
Published online: 2019-03-15

Abstract

Ewing sarcoma is a group of low-differentiated, high-grade, small-cell tumours. It is the third most common malignancy among primary bone tumours in adults. The prognosis of Ewing sarcoma is bad, and very often at the time of diagnosis the disease is highly advanced. For patients with localized disease, who have no metastases diagnosed at baseline, it is necessary to use combined treatment. It consists of induction chemotherapy (12–18 weeks) + local treatment (surgery ± radiotherapy or radiotherapy), and is followed by adjuvant consolidation chemotherapy. The whole treatment takes about 48–52 weeks. Advances in multidisciplinary treatment, including combined chemotherapy, surgery and radiotherapy have resulted in a significant improvement in patients’ quality of life and prognosis. Clinical trials are currently underway and new treatment standards are being developed.

Abstract

Ewing sarcoma is a group of low-differentiated, high-grade, small-cell tumours. It is the third most common malignancy among primary bone tumours in adults. The prognosis of Ewing sarcoma is bad, and very often at the time of diagnosis the disease is highly advanced. For patients with localized disease, who have no metastases diagnosed at baseline, it is necessary to use combined treatment. It consists of induction chemotherapy (12–18 weeks) + local treatment (surgery ± radiotherapy or radiotherapy), and is followed by adjuvant consolidation chemotherapy. The whole treatment takes about 48–52 weeks. Advances in multidisciplinary treatment, including combined chemotherapy, surgery and radiotherapy have resulted in a significant improvement in patients’ quality of life and prognosis. Clinical trials are currently underway and new treatment standards are being developed.
Get Citation

Keywords

Ewing sarcoma; diagnosis; therapy; prognosis

About this article
Title

Ewing sarcoma

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 6 (2018)

Article type

Review paper

Pages

392-398

Published online

2019-03-15

DOI

10.5603/OCP.2018.0052

Bibliographic record

Oncol Clin Pract 2018;14(6):392-398.

Keywords

Ewing sarcoma
diagnosis
therapy
prognosis

Authors

Tomasz Świtaj
Paulina Jagodzińska-Mucha

References (22)
  1. Casali PG, Bielack S, Abecassis N, et al. ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Supplement_4): iv79–iv95.
  2. Gerrand C, Athanasou N, Brennan B, et al. British Sarcoma Group. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016; 6: 7.
  3. Rutkowski P, Świtaj T. Bone sarcomas. Oncol Clin Pract. 2018; 14(3): 115–128.
  4. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. 2018; 1.
  5. Rutkowski P. Mięsaki kości. Viamedica Gdańsk. 2016.
  6. Le Deley MC, Paulussen M, Lewis I, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014; 32(23): 2440–2448.
  7. Denbo JW, Shannon Orr W, Wu Y, et al. Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol. 2012; 19(12): 3809–3815.
  8. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003; 55(1): 168–177.
  9. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010; 28(20): 3284–3291.
  10. Schuck A, Hofmann J, Rübe C, et al. Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys. 1998; 42(5): 1001–1006.
  11. Bacci G, Palmerini E, Staals EL, et al. Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy. Radiother Oncol. 2009; 93(2): 383–387.
  12. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18(17): 3108–3114.
  13. Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990; 8(10): 1664–1674.
  14. Miser JS, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348(8): 694–701.
  15. Paulussen M, Craft AW, Lewis I, et al. European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008; 26(27): 4385–4393.
  16. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010; 28(20): 3284–3291.
  17. Whelan J, Le Deley MC, Dirksen U, et al. Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 [Epub ahead of print]: JCO2018782516.
  18. Gorlick R, Janeway KA, Adamson PC. Dose Intensification Improves the Outcome of Ewing Sarcoma. J Clin Oncol. 2018 [Epub ahead of print]: JCO2018793489.
  19. Euro Ewing 2012 protocol_version 5.0. http://www.euroewing.eu/clinical-trials/ee2012-trial/ee2012-update (2 Jun 2017).
  20. Zhou Z, Guan H, Duan X, et al. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005; 104(8): 1713–1720.
  21. Odri GA, Dumoucel S, Picarda G, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010; 70(19): 7610–7619.
  22. Italiano A, Katz D. Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative study. Presented at: the ESMO 2018 Congress; Munich, Germany: October 19-23, 2018. Abstract LBA67.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl